Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HFB200301 + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HFB200301 | HFB 200301|HFB-200301 | HFB200301 is an antibody that targets TNFR2, potentially resulting in enhanced anti-tumor immune response (Cancer Res (2021) 81 (13_Supplement): 1883). | ||
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |